The stock of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) is a huge mover today! About 68,691 shares traded or 48.52% up from the average. DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has declined 62.11% since September 9, 2016 and is downtrending. It has underperformed by 72.51% the S&P500.The move comes after 6 months positive chart setup for the $30.56 million company. It was reported on Apr, 18 by Barchart.com. We have $3.00 PT which if reached, will make NASDAQ:DMPI worth $1.53M more.
La-Z-Boy Incorporated manufactures, markets, imports, exports, distributes and retails upholstery furniture products. The company has market cap of $1.32 billion. The Firm also imports, distributes and retails accessories and casegoods furniture products. It has a 16.64 P/E ratio. The Company’s divisions include the Upholstery segment, the Casegoods segment and the Retail segment.
Analysts await DelMar Pharmaceuticals Inc (NASDAQ:DMPI) to report earnings on May, 11. They expect $-0.15 EPS, down 25.00% or $0.03 from last year’s $-0.12 per share. After $-0.13 actual EPS reported by DelMar Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The company has market cap of $30.56 million. The Firm focuses on the treatment of cancer. It currently has negative earnings. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme , a form of brain cancer.
Analysts await La-Z-Boy Incorporated (NYSE:LZB) to report earnings on June, 20. They expect $0.46 earnings per share, down 11.54% or $0.06 from last year’s $0.52 per share. LZB’s profit will be $22.61 million for 14.59 P/E if the $0.46 EPS becomes a reality. After $0.47 actual earnings per share reported by La-Z-Boy Incorporated for the previous quarter, Wall Street now forecasts -2.13% negative EPS growth.
Since January 1, 0001, it had 0 insider buys, and 5 sales for $1.65 million activity.
Ratings analysis reveals 43% of La-Z-Boy’s analysts are positive. Out of 7 Wall Street analysts rating La-Z-Boy, 3 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $28 while the high is $32. The stock’s average target of $30 is 11.73% above today’s ($26.85) share price. LZB was included in 8 notes of analysts from August 20, 2015. The firm has “Hold” rating by BB&T Capital given on Wednesday, January 27. KeyBanc Capital Markets maintained La-Z-Boy Incorporated (NYSE:LZB) rating on Thursday, October 6. KeyBanc Capital Markets has “Overweight” rating and $28 target. As per Wednesday, March 2, the company rating was initiated by Sidoti. Stifel Nicolaus downgraded the shares of LZB in report on Thursday, February 23 to “Hold” rating. The rating was downgraded by Raymond James to “Mkt Perform” on Thursday, January 5. Longbow initiated the shares of LZB in report on Friday, August 5 with “Neutral” rating. Barrington Research maintained the stock with “Outperform” rating in Thursday, August 20 report. The firm earned “Hold” rating on Tuesday, August 18 by Zacks.
Botty Investors Llc holds 11.13% of its portfolio in La-Z-Boy Incorporated for 609,135 shares. Skyline Asset Management Lp owns 840,000 shares or 1.73% of their US portfolio. Moreover, Smith Graham & Co. Investment Advisors Lp has 1.05% invested in the company for 313,059 shares. The Michigan-based Regal Investment Advisors Llc has invested 1.03% in the stock. Monroe Bank & Trust Mi, a Michigan-based fund reported 91,820 shares.
